Van beleggers
voor beleggers
desktop iconMarkt Monitor

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel RELIEF THERAPEUTICS N ZSE:RLF.CH, CH1251125998

  • 3,840 2 jun 2023 17:30
  • +0,040 (+1,05%) Dagrange 3,700 - 3,890
  • 20.508 Gem. (3M) 3,5M

Relief therapeutics Holding

9.097 Posts
Pagina: «« 1 ... 443 444 445 446 447 ... 455 »» | Laatste | Omlaag ↓
  1. Beso 9 januari 2022 09:39
    Bericht spreekt ook over Aviptadil dus RLF negeren ze niet. NRX heeft volgens mij niet de beste kaarten om te winnen en ik vermoed dat ze dit ook beseffen. Stijging vorige week is hopelijk begin van een upwaartse trend en daling vrijdag een gezonde adempauze.
    Succes aan alle geïnvesteerden.
  2. Belegger 86 9 januari 2022 10:09
    quote:

    M c M schreef op 9 januari 2022 03:32:

    [...]

    Wat verwacht je hiervan? Denk eerlijk gezegd niet dat hij opeens positief over Relief zal zijn. In het grote moddervechten zie ik dit dan ook niet als iets positiefs voor dit aandeel. Voor NRX trouwens ook niet want daar lijkt men die man met z'n verhalen ook niet echt meer serieus te nemen.

    Disclaimer; ik sta er momenteel zelf even buiten na stijging van donderdag
    Ik verwacht hier zelf van dat er weinig concreet nieuws voorbij komt.

    Jammer dat het allemaal zo lang moet duren en dat het nog steeds een moddergevecht is.
    Eerst was Dr Javitt nog de verlosser met zijn ervaring, kan snel gaan.

    Heb nog een klein portie die ik zal afbouwen als er ooit nog is goed nieuws komt.mbt de rechtzaak of aviptadil en anders wordt het long term.
  3. Beso 12 januari 2022 07:42
    relieftherapeutics.com/newsblog/relie...

    Vooral laatste zin waarvan ik hoop dat ze eind februari een vriendschappelijke regeling kunnen vinden :
    Finally, Relief reports that its previously announced mediation with NeuroRx, seeking to amicably resolve the litigation between the parties, remains scheduled for late February 2022 and that, notwithstanding the filing of the new complaint, Relief intends to participate in the upcoming mediation.
  4. Beso 12 januari 2022 07:47
    Randbemerkingen omtrent het lopende proces :

    - grote investeerders zijn aan boord gebleven
    - als ze voor gerecht gaan is het omdat er geld te rapen valt
    - Aviptadil heeft zijn werkzaamheid al getoond en is niet hun enige product in de pipeline
    - persoonlijk denk ik dat de aandelenkoers te zeer afgestraft werd door deze hangende rechtszaak en te lang uitblijven van resultaten goedkeuring deels als gevolg hiervan.

  5. M c M 17 januari 2022 04:24
    quote:

    Beso schreef op 14 januari 2022 07:44:

    De soap gaat verder : relieftherapeutics.com/newsblog/relie...
    Ja nog niet eerder meegemaakt zoveel moddergooien over en weer. NRXP inmiddels alweer 2x terug gereageerd volgens mij.
    Ben bang dat dit tot en met 21 februari minimaal doorgaat.
    Lijkt me momenteel geen goede basis om hier in te zitten.
    Na de 15e februari kijk ik weer waar het staat of het interessant is. Of eventueel de 'malafide' andere kant.

    Afstand nemen van een bedrijf en product waar je wel in gelooft/geloofde is wel een vak trouwens.. ;-)
  6. RodgerRodger 19 januari 2022 07:38
    Dear Sir or Madam,

    We would like to draw your attention to the following ad hoc announcement pursuant to Art. 53 LR of RELIEF THERAPEUTICS Holding SA:

    Relief Reports that its U.S. Collaboration Partner has Announced Expansion of Aviptadil U.S. Expanded Access and Right to Try Programs for Patients With COVID-19 Respiratory Failure who Have Exhausted All Approved Therapies

    Geneva, Switzerland, January 19, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”), of its collaboration partner with respect to aviptadil, NeuroRx, Inc. ("NeuroRx"), has announced enhancements to its Expanded Access and Right to Try programs. The press release states that these programs enable patients with respiratory failure from COVID-19, who have tried all approved medicines, including remdesivir, and who are not able to participate in a clinical study, to receive aviptadil upon a physician’s prescription. According to the press release, NRx will continue to provide aviptadil to hospitals enrolled in NRx’s Expanded Access Protocol under U.S. Food and Drug Administration guidelines. The press release also reported that NRx is also making aviptadil available as an investigational medicine under the Federal Right to Try Act. The related NRx press release can be accessed through the following link.

    ABOUT RELIEF
    Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate, RLF-100™ (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19 through Relief’s collaboration partner in the U.S., NeuroRx. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. Finally, Relief's recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed and development-stage programs.

    RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit www.relieftherapeutics.com.

    Follow us on LinkedIn.

    CONTACT:
    RELIEF THERAPEUTICS Holding SA
    Jack Weinstein
    Chief Financial Officer and Treasurer
    contact@relieftherapeutics.com

    FOR MEDIA/INVESTOR INQUIRIES:
    Rx Communications Group
    Michael Miller
    +1-917-633-6086
    mmiller@rxir.com


    Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether NeuroRx's recently submitted application to the FDA seeking EUA for aviptadil to treat patients with critical COVID-19 who are at immediate risk of death from respiratory failure despite treatment with approved therapy including Remdesivir and who are ineligible for enrollment into the ACTIV-3b NIH-sponsored trial will be approved, (ii) whether RELIEF THERAPEUTICS Holding SA will be successful in its lawsuit against NRx's subsidiary, NeuroRx, and NeuroRx's CEO, Jonathan Javitt, and in defending NeuroRx’s recently filed lawsuit against Relief, (iii) whether the upcoming mediation between the parties to the disputes between Relief and NeuroRx will be successful, (iv) whether aviptadil will ever be approved in the U.S., the U.K., or the E.U. for the treatment of respiratory failure in patients with COVID-19 or any other disease, and (v) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
  7. RodgerRodger 27 januari 2022 07:35
    Dear Sir or Madam,

    We would like to draw your attention to the following ad hoc announcement pursuant to Art. 53 LR of RELIEF THERAPEUTICS Holding SA:

    Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge

    Geneva, Switzerland, January 27, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”), of its collaboration partner with respect to aviptadil, NeuroRx, Inc. ("NeuroRx"), has announced receipt of a first safety report from a Southwestern hospital where physicians have administered aviptadil to patients with COVID-19 respiratory failure. According to the press release, the patients were treated under the Federal Right to Try Law that gives access to investigational medicines for patients who have been diagnosed with life-threatening diseases or conditions, who have tried all approved treatment options, and who are unable to participate in a clinical trial to access certain unapproved treatments. The press release stated that of the first 19 patients treated by December 31, 2021, three had died and 16 (84%) were reported to be alive by January 22, 2022. The release also reported that this Right to Try use of aviptadil occurred during the current Omicron surge, although patients were not necessarily tested for the specific COVID variant that caused their ICU admission. NRx reported that no serious adverse events were reported. The related NRx press release can be accessed through the following link.
  8. forum rang 10 DeZwarteRidder 27 januari 2022 09:11
    quote:

    RodgerRodger schreef op 27 januari 2022 07:35:

    Dear Sir or Madam,

    We would like to draw your attention to the following ad hoc announcement pursuant to Art. 53 LR of RELIEF THERAPEUTICS Holding SA:

    Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge

    Geneva, Switzerland, January 27, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”), of its collaboration partner with respect to aviptadil, NeuroRx, Inc. ("NeuroRx"), has announced receipt of a first safety report from a Southwestern hospital where physicians have administered aviptadil to patients with COVID-19 respiratory failure. According to the press release, the patients were treated under the Federal Right to Try Law that gives access to investigational medicines for patients who have been diagnosed with life-threatening diseases or conditions, who have tried all approved treatment options, and who are unable to participate in a clinical trial to access certain unapproved treatments. The press release stated that of the first 19 patients treated by December 31, 2021, three had died and 16 (84%) were reported to be alive by January 22, 2022. The release also reported that this Right to Try use of aviptadil occurred during the current Omicron surge, although patients were not necessarily tested for the specific COVID variant that caused their ICU admission. NRx reported that no serious adverse events were reported. The related NRx press release can be accessed through the following link.
    Nog meer f(l)opnieuws.
  9. M c M 29 januari 2022 04:06
    quote:

    RodgerRodger schreef op 27 januari 2022 07:35:

    Dear Sir or Madam,

    We would like to draw your attention to the following ad hoc announcement pursuant to Art. 53 LR of RELIEF THERAPEUTICS Holding SA:

    Relief Reports that its U.S. Collaboration Partner has Announced Receipt of Initial Report of Patient Safety and Survival from Right to Try Use of Aviptadil During Omicron Surge

    Geneva, Switzerland, January 27, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”), of its collaboration partner with respect to aviptadil, NeuroRx, Inc. ("NeuroRx"), has announced receipt of a first safety report from a Southwestern hospital where physicians have administered aviptadil to patients with COVID-19 respiratory failure. According to the press release, the patients were treated under the Federal Right to Try Law that gives access to investigational medicines for patients who have been diagnosed with life-threatening diseases or conditions, who have tried all approved treatment options, and who are unable to participate in a clinical trial to access certain unapproved treatments. The press release stated that of the first 19 patients treated by December 31, 2021, three had died and 16 (84%) were reported to be alive by January 22, 2022. The release also reported that this Right to Try use of aviptadil occurred during the current Omicron surge, although patients were not necessarily tested for the specific COVID variant that caused their ICU admission. NRx reported that no serious adverse events were reported. The related NRx press release can be accessed through the following link.

    Dit begint wel hele bizarre vormen aan te nemen qua PR's haha. Je weet eigenlijk helemaal niks na het lezen ervan. 3 van de 19 dood klinkt mij niet positief in de oren. Zeker niet voor de Omicron variant want die doodt praktisch niet. Maar ja, variant wordt niet vermeldt. Verder nog minimaal 10 vragen in mn hoofd waar ik niemand een plezier mee doe, daar wordt ook niets over vermeld..

  10. forum rang 10 DeZwarteRidder 29 januari 2022 08:32
    quote:

    M c M schreef op 29 januari 2022 04:06:

    [...]Dit begint wel hele bizarre vormen aan te nemen qua PR's haha. Je weet eigenlijk helemaal niks na het lezen ervan. 3 van de 19 dood klinkt mij niet positief in de oren. Zeker niet voor de Omicron variant want die doodt praktisch niet. Maar ja, variant wordt niet vermeldt. Verder nog minimaal 10 vragen in mn hoofd waar ik niemand een plezier mee doe, daar wordt ook niets over vermeld..
    McM zegt met zoveel woorden dat hij het helemaal met mijn kritiek eens is.

    De hele gang van zaken is absurd en belachelijk.
  11. M c M 29 januari 2022 23:21
    quote:

    DeZwarteRidder schreef op 29 januari 2022 08:32:

    [...]

    McM zegt met zoveel woorden dat hij het helemaal met mijn kritiek eens is.

    De hele gang van zaken is absurd en belachelijk.
    Ja, mbt de laatste paar persberichten zeker.
    Om die reden bij de vorige Spike-up ze van de hand gedaan. Wel een paar cent te vroeg helaas.

    Jouw kritiek zelf vond ik nogal summier en de onderbouwing ontbrak een beetje.

    De vraag is nu hoe het eind februari uit zal pakken in de rechtzaal. Iemand daar een onderbouwde mening over?
9.097 Posts
Pagina: «« 1 ... 443 444 445 446 447 ... 455 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

RELIEF THERAPEUTICS N Meer »

Koers 3,840   Verschil +0,04 (+1,05%)
Laag 3,700   Volume 20.508
Hoog 3,890   Gem. Volume 3.483.534
2 jun 2023 17:30
Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en tips?

Neem nu een abonnement op IEX en krijg toegang tot onze koop-en verkooptips!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links